ATE516263T1 - Amine, die einen säugetier-anandamidtransporter hemmen; und verfahren zu deren verwendung - Google Patents
Amine, die einen säugetier-anandamidtransporter hemmen; und verfahren zu deren verwendungInfo
- Publication number
- ATE516263T1 ATE516263T1 AT03736639T AT03736639T ATE516263T1 AT E516263 T1 ATE516263 T1 AT E516263T1 AT 03736639 T AT03736639 T AT 03736639T AT 03736639 T AT03736639 T AT 03736639T AT E516263 T1 ATE516263 T1 AT E516263T1
- Authority
- AT
- Austria
- Prior art keywords
- amines
- present
- relates
- methods
- diseases
- Prior art date
Links
- 150000001412 amines Chemical class 0.000 title abstract 4
- 241000124008 Mammalia Species 0.000 title abstract 2
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 title abstract 2
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 208000037415 AIDS wasting syndrome Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 208000006561 Cluster Headache Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 208000003577 HIV wasting syndrome Diseases 0.000 abstract 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 208000008238 Muscle Spasticity Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 206010049771 Shock haemorrhagic Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 208000018912 cluster headache syndrome Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 206010036596 premature ejaculation Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 208000018198 spasticity Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B20/00—Methods specially adapted for identifying library members
- C40B20/08—Direct analysis of the library members per se by physical methods, e.g. spectroscopy
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Structural Engineering (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38104102P | 2002-05-16 | 2002-05-16 | |
| PCT/US2003/015581 WO2003097573A1 (en) | 2002-05-16 | 2003-05-15 | Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE516263T1 true ATE516263T1 (de) | 2011-07-15 |
Family
ID=29550057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03736639T ATE516263T1 (de) | 2002-05-16 | 2003-05-15 | Amine, die einen säugetier-anandamidtransporter hemmen; und verfahren zu deren verwendung |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7049329B2 (enExample) |
| EP (1) | EP1509489B1 (enExample) |
| JP (1) | JP4488350B2 (enExample) |
| KR (1) | KR101087883B1 (enExample) |
| AT (1) | ATE516263T1 (enExample) |
| AU (1) | AU2003237882B2 (enExample) |
| CA (1) | CA2486055C (enExample) |
| MX (1) | MXPA04011390A (enExample) |
| NZ (2) | NZ537225A (enExample) |
| WO (1) | WO2003097573A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1383465B1 (en) * | 2001-03-29 | 2011-08-10 | Michael Davis | Acute pharmacologic augmentation of psychotherapy with d-cycloserine |
| AU2003237882B2 (en) * | 2002-05-16 | 2010-04-08 | Sunovion Pharmaceuticals Inc. | Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| FR2864080B1 (fr) * | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| FR2866888B1 (fr) * | 2004-02-26 | 2006-05-05 | Sanofi Synthelabo | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique |
| US20060084659A1 (en) * | 2004-10-19 | 2006-04-20 | Michael Davis | Augmentation of psychotherapy with cannabinoid reuptake inhibitors |
| WO2006116773A2 (en) * | 2005-04-28 | 2006-11-02 | The Regents Of The University Of California | Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders |
| WO2010083532A1 (en) * | 2009-01-19 | 2010-07-22 | The Research Foundaton Of State University Of New York | Fatty acid binding proteins as drug targets for modulation of endocannabinoids |
| ES2708723T3 (es) | 2011-08-19 | 2019-04-10 | Univ California | Inhibidores de FAAH restringidos de forma periférica sustituidos en posición meta por bifenilo |
| ES2908240T3 (es) | 2014-04-07 | 2022-04-28 | Univ California | Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos |
| FR3071833B1 (fr) * | 2017-09-29 | 2020-01-03 | Universite Paris-Sud | Nouveau procede de synthese d'amines tertiaires dissymetriques |
| US10414721B1 (en) | 2018-06-04 | 2019-09-17 | University Of Bern | Inhibitor of endocannabinoid cellular reuptake |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US504455A (en) | 1893-09-05 | Storage-battery | ||
| US2601275A (en) * | 1949-10-29 | 1952-06-24 | Givaudan Corp | Aromatic chlorethylamines and their salts |
| US2778826A (en) * | 1954-04-26 | 1957-01-22 | Rohm & Haas | Preparation of basic nitrogen compounds |
| DE4219975A1 (de) * | 1992-06-19 | 1993-12-23 | Basf Ag | Substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung |
| CA2192965C (en) | 1994-07-11 | 2007-12-04 | David W. Pate | Anandamide analogue compositions and method of treating intraocular hypertension using same |
| US5688825A (en) | 1996-05-31 | 1997-11-18 | University Of Connecticut | Anandamide amidase inhibitors as analgesic agents |
| JP3824735B2 (ja) * | 1997-05-13 | 2006-09-20 | ポーラ化成工業株式会社 | アミン誘導体 |
| US6200951B1 (en) * | 1998-03-12 | 2001-03-13 | Icos Corporation | Chitinase chitin-binding fragments |
| EP1084098A4 (en) * | 1998-06-09 | 2004-12-22 | Univ Connecticut | INHIBITORS OF THE ANANDAMIDE TRANSPORTER AS ANALGETIC AGENT |
| US6335023B1 (en) * | 1999-06-30 | 2002-01-01 | Ruey J. Yu | Oligosaccharide aldonic acids and their topical use |
| US6696412B1 (en) * | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| US20020019444A1 (en) | 2000-05-08 | 2002-02-14 | Edward Hogestatt | Anandamide and structurally related lipids as vanilloid receptor modulators |
| SK16612002A3 (sk) * | 2000-06-02 | 2004-04-06 | Pfizer Products Inc. | Deriváty hygromycínu A na použitie na liečenie bakteriálnych a protozoálnych infekcií |
| FR2824324B1 (fr) * | 2001-05-04 | 2003-08-15 | Aventis Pharma Sa | Nouveaux derives d'azole ou de triazole, leur procede de preparation et leur application comme medicaments anti-fongiques |
| AU2003237882B2 (en) * | 2002-05-16 | 2010-04-08 | Sunovion Pharmaceuticals Inc. | Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
-
2003
- 2003-05-15 AU AU2003237882A patent/AU2003237882B2/en not_active Ceased
- 2003-05-15 US US10/439,347 patent/US7049329B2/en not_active Expired - Lifetime
- 2003-05-15 NZ NZ537225A patent/NZ537225A/en not_active IP Right Cessation
- 2003-05-15 MX MXPA04011390A patent/MXPA04011390A/es active IP Right Grant
- 2003-05-15 EP EP03736639A patent/EP1509489B1/en not_active Expired - Lifetime
- 2003-05-15 JP JP2004505307A patent/JP4488350B2/ja not_active Expired - Fee Related
- 2003-05-15 AT AT03736639T patent/ATE516263T1/de not_active IP Right Cessation
- 2003-05-15 CA CA2486055A patent/CA2486055C/en not_active Expired - Fee Related
- 2003-05-15 WO PCT/US2003/015581 patent/WO2003097573A1/en not_active Ceased
- 2003-05-15 KR KR1020047018474A patent/KR101087883B1/ko not_active Expired - Fee Related
- 2003-05-15 NZ NZ570989A patent/NZ570989A/en not_active IP Right Cessation
-
2006
- 2006-05-23 US US11/439,529 patent/US7511073B2/en not_active Expired - Lifetime
-
2009
- 2009-02-25 US US12/392,981 patent/US7671087B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| NZ537225A (en) | 2008-09-26 |
| CA2486055A1 (en) | 2003-11-27 |
| US20040048907A1 (en) | 2004-03-11 |
| AU2003237882B2 (en) | 2010-04-08 |
| MXPA04011390A (es) | 2005-02-17 |
| US7511073B2 (en) | 2009-03-31 |
| EP1509489A1 (en) | 2005-03-02 |
| KR20050012246A (ko) | 2005-01-31 |
| US7049329B2 (en) | 2006-05-23 |
| JP4488350B2 (ja) | 2010-06-23 |
| AU2003237882A1 (en) | 2003-12-02 |
| NZ570989A (en) | 2010-01-29 |
| WO2003097573A1 (en) | 2003-11-27 |
| CA2486055C (en) | 2012-03-06 |
| US20060281742A1 (en) | 2006-12-14 |
| EP1509489A4 (en) | 2007-03-21 |
| JP2005526133A (ja) | 2005-09-02 |
| KR101087883B1 (ko) | 2011-11-30 |
| EP1509489B1 (en) | 2011-07-13 |
| US20090163593A1 (en) | 2009-06-25 |
| US7671087B2 (en) | 2010-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE516263T1 (de) | Amine, die einen säugetier-anandamidtransporter hemmen; und verfahren zu deren verwendung | |
| Caron et al. | Preparation and utility of trihaloethyl imidates: useful reagents for the synthesis of amidines | |
| ATE490253T1 (de) | Synthese von 5-substituierten 7-azaindolen und 7- azaindolinen | |
| ATE542818T1 (de) | Imidazo- und triazolopyridinverbindungen und verfahren zu deren anwendung | |
| EP1752567A4 (en) | METHOD FOR PRODUCING A WATER OF SILICON CARBIDE EINSTRISTALL | |
| DE602004017196D1 (de) | Kondensierte azabicyclische verbindungen, die den vanilloidrezeptorsubtyp 1 (vr1)- rezeptor inhibieren | |
| BRPI0412667A (pt) | sìntese regiosseletiva de cci - 779 | |
| NO20060167L (no) | Benzamidderivat eller salt derav | |
| SE0202134D0 (sv) | Therapeutic agents | |
| WO2008064342A3 (en) | Pde10 inhibitors and related compositions and methods | |
| JPWO2003053927A1 (ja) | ピペラジン誘導体 | |
| CA2570197A1 (en) | Nk1 antagonists | |
| JO2926B1 (en) | Organic compounds | |
| ATE345334T1 (de) | Umgelagerte pentanole, ein verfahren zu ihrer herstellung und ihre verwendung als entz ndungshemmer | |
| FR2853650B1 (fr) | Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance | |
| EP1970444A4 (en) | METHOD FOR THE PRODUCTION OF AN ANTIGEN-SPECIFIC HYBRIDOMA USING AN ARTIFICIAL LYMPHOTIC NODE WITH GOOD EFFICIENCY | |
| ATE392400T1 (de) | Suspensionsverfahren für die kohlenwasserstoffsynthese mit insitu hydroisomerierung von synthetisierter kohlenwassersrtoffflüssigkeit. | |
| IT1390756B1 (it) | Processo per la sintesi di carbapenem mediante l'uso di nickel raney | |
| EP1961733A4 (en) | PROCESS FOR SELECTIVELY PREPARING A PRIMARY AMINE COMPOUND | |
| US20120172605A1 (en) | Method for producing asymmetric tetrasubstituted carbon atom-containing compound | |
| JP2005526133A5 (enExample) | ||
| DE602004025935D1 (de) | Histondeacetylaseinhibitor und verfahren zu dessen herstellung | |
| ES2247347T3 (es) | Nuevos derivados de indol. | |
| EP1813596A4 (en) | PROCESS FOR PREPARING ALPHA, ALPHA-DIFLUORAMINE | |
| ATE478854T1 (de) | Verfahren zur herstellung von ä2-(3,3,5,5- tetramethylcyclohexyl)phenylüpiperazin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |